Importantly, large cohort sequencing data suggest that individuals with TET2 mutations are also at a high risk of developing hematologic malignancies, such as myelodysplastic neoplasms, myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML) [3–6]. This evidence concerns the gene TET2 and myeloproliferative disorder.